Cargando…

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease

BACKGROUND AND OBJECTIVE: Anemia caused by iron depletion is common in patients with hemodialysis-dependent stage 5 chronic kidney disease (CKD-5HD) patients. To maintain the iron levels, external administration of iron is essential. Ferric pyrophosphate citrate (FPC) is a novel, water-soluble compl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gan, Liangying, Xie, Panpan, Tan, Yan, Wei, Gang, Yuan, Xiaojuan, Lu, Zhifei, Pratt, Raymond, Zhou, Yongchun, Hui, Ai-Min, Li, Kexin, Fang, Yi, Zuo, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167373/ https://www.ncbi.nlm.nih.gov/pubmed/35380419 http://dx.doi.org/10.1007/s40268-022-00384-5

Ejemplares similares

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis
por: Zhang, Lingxiao, et al.
Publicado: (2022)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Physicochemical characterization of ferric pyrophosphate citrate
por: Gupta, Ajay, et al.
Publicado: (2018)

Ferric pyrophosphate citrate: interactions with transferrin
por: Pratt, Raymond, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients
por: Fishbane, Steven N., et al.
Publicado: (2015)

Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022)

Antiviral effects of ferric ammonium citrate
por: Wang, Hongbin, et al.
Publicado: (2018)

Intestinal Absorption Study of a Granular Form of Ferric Pyrophosphate
por: Micheletto, Marta, et al.
Publicado: (2022)

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial
por: Hanudel, Mark R., et al.
Publicado: (2022)

Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
por: Ganz, Tomas, et al.
Publicado: (2019)

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017)

Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review
por: Zhao, Yuchao, et al.
Publicado: (2022)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Reduction of costs for anemia-management drugs associated with the use of ferric citrate
por: Thomas, Anila, et al.
Publicado: (2014)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
por: Hain, Debra J., et al.
Publicado: (2017)

Ferric citrate is a safe and digestible source of iron in broilers and piglets
por: Männer, Klaus, et al.
Publicado: (2021)

Ferric Citrate Uptake Is a Virulence Factor in Uropathogenic Escherichia coli
por: Frick-Cheng, Arwen E., et al.
Publicado: (2022)

The fciTABC and feoABI systems contribute to ferric citrate acquisition in Stenotrophomonas maltophilia
por: Liao, Chun-Hsing, et al.
Publicado: (2022)

High Bioavailability from Ferric Pyrophosphate-Fortified Bouillon Cubes in Meals is Not Increased by Sodium Pyrophosphate: a Stable Iron Isotope Study in Young Nigerian Women
por: Eilander, Ans, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
por: Cong, Duanduan, et al.
Publicado: (2022)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease
por: Hanudel, Mark R., et al.
Publicado: (2022)

Hydrolysis of Extracellular Pyrophosphate increases in post-hemodialysis plasma
por: Azpiazu, Daniel, et al.
Publicado: (2018)

Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial
por: Lee, Chien-Te, et al.
Publicado: (2022)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells
por: Scheers, Nathalie M., et al.
Publicado: (2018)

Ferric Citrate Hydrate Has Little Impact on Hyperplasia of Enterochromaffin Cells in the Rat Small Intestine Compared to Sodium Ferrous Citrate
por: Machida, Takuji, et al.
Publicado: (2022)

Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study
por: Ito, Kyoko, et al.
Publicado: (2021)

Oral Iron Absorption of Ferric Citrate Hydrate and Hepcidin-25 in Hemodialysis Patients: A Prospective, Multicenter, Observational Riona-Oral Iron Absorption Trial
por: Tomosugi, Naohisa, et al.
Publicado: (2023)

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats
por: IIDA, Akio, et al.
Publicado: (2020)

Pharmacokinetics and absorption mechanism of tandospirone citrate
por: Li, Rong, et al.
Publicado: (2023)

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
por: Lacquaniti, Antonio, et al.
Publicado: (2020)

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease
por: Wu, Mei-Yi, et al.
Publicado: (2017)

Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report
por: Kobayashi, Hiroshi, et al.
Publicado: (2022)

Ferric citrate and apo-transferrin enable erythroblast maturation with β-globin from hemogenic endothelium
por: Jeon, Soo-Been, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gl476hhf1i3096u3vsb5o9v62h